Nektar Therapeutics (NKTR) — Cash Flow Reinvestment Rate

Latest as of June 2018: 0.93x

Nektar Therapeutics (NKTR) has a Cash Flow Reinvestment Rate of 0.93x as of June 2018, reinvesting $897.05 Million (capex $2.75 Million plus investments $-894.30 Million) from operating cash flow of $959.64 Million. Explore how much does Nektar Therapeutics reinvest in capital to see what proportion of operating cash flow is directed to capital expenditures.

Reinvestment Rate

0.93x
(Capex + Investments) / Operating CF

Total Reinvested

$897.05 Million
Capex + Investments

Operating Cash Flow

$959.64 Million
USD

Capital Expenditures

$2.75 Million
USD

Nektar Therapeutics Cash Flow Reinvestment Rate (1997–2018)

Historical reinvestment intensity for Nektar Therapeutics across 4 annual periods. Also explore Nektar Therapeutics assets under control for the complete picture of this company's asset base.

Annual Cash Flow Reinvestment Rate for Nektar Therapeutics (1997–2018)

Year-by-year capital reinvestment analysis for Nektar Therapeutics. For live market cap and broader valuation context, see Nektar Therapeutics stock valuation.

Year Reinvestment Rate Total Reinvested (USD) Operating CF Capex YoY Change
2018 1.93x $1.38 Billion $718.21 Million $14.24 Million ▲ +269.5%
2009 0.52x $20.70 Million $39.74 Million $20.70 Million ▲ +132.4%
2007 0.22x $32.80 Million $146.30 Million $32.80 Million ▼ -93.5%
1997 3.47x $17.26 Million $4.98 Million $17.26 Million
Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow